EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs

Jirawan Vienghirun iD, Ratree Sawangjit iD, Saithip Suttiruksa, Nathorn Chaiyakunapruk iD, Peerawat Jinathongthai, Kamlesh Khunti iD, Shaun Wen Huey Lee iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70698 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jirawan Vienghirun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Mahasarakham University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study used a network meta‐analysis (NMA) as the primary approach to compare the efficacy and tolerability of GLP‐1 receptor agonists and dual agonists in overweight or obese adults with and without Type 2 diabetes. Materials and Methods PubMed, Embase, Scopus, CENTRAL, and trial registries were searched through April 30, 2025. Randomized clinical trials (RCTs) of GLP‐1 receptor agonists in adults with and without Type 2 diabetes were included. Data were extracted according to PRISMA 2020. Pairwise and using random‐effects models were performed, with treatment rankings derived using SUCRA. Outcomes included ≥ 5% and ≥ 10% weight loss, weight change (absolute and percentage weight loss) at 24–52 weeks, and adverse events.

Results

A total of 127 RCTs (58 976) Participants; (39 520 with and 19 456 without T2DM) assessed seven GLP‐1RAs. Compared to placebo, NMA indicated that tirzepatide, subcutaneous semaglutide (Semaglutide_SC), and oral semaglutide (Semaglutide_oral) increased ≥ 5% weight loss (RR 7.17 [95% CI 4.38–11.73], 4.74 [3.17–7.08], 2.85 [1.78–4.58]) in T2DM. Only tirzepatide and Semaglutide_SC were effective (2.99 [1.20–7.44], 2.75 [1.14–6.61]) in non‐T2DM. For ≥ 10% loss, tirzepatide was most effective (14.34 [5.98–34.35]), followed by Semaglutide_oral (6.86 [2.63–17.90]) and Semaglutide_SC (6.12 [2.97–12.59]) in T2DM. In non‐T2DM, Semaglutide_SC (10.72 [3.29–34.90]) and tirzepatide (4.70 [1.02–21.73]) were effective when compared to placebo. Mixed treatment effects (direct head to head and indirect comparisons) showed that tirzepatide reduced weight more than Semaglutide_oral (MD –6.75% [−8.34 to −5.17]) and Semaglutide_SC (−4.94% [−6.35 to −3.52]) in T2DM and was the only effective agent in non‐T2DM (−16.48% [−21.70 to −11.27]) when compared to placebo. Higher doses enhanced weight loss; nausea/vomiting were more common with tirzepatide (RR 3.64 [2.40–5.52]).

Conclusions

Tirzepatide and Semaglutide_SC are most effective for clinically meaningful weight loss. Optimal dosing and adherence remain essential in practice. Trail Registration: PROSPERO (CRD42024539634).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2ObesityOverweightHypoglycemic AgentsHumansRandomized Controlled Trials as TopicSemaglutideTirzepatideGlucagon-Like PeptidesGlucagon-Like Peptide-1 ReceptorAnti-Obesity AgentsTreatment Outcome

Stichwörter der Autor:innen

GLP‐1 receptor/dual agonists (GLP‐1RAs)non‐T2DMobesitysemaglutidetirzepatideweight loss

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideGlucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 ReceptorAnti-Obesity Agents

Autor:innen und Institutionen

  • Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
  • Clinical Trials and Evidence-Based Syntheses Research Unit (CTEBs RU), Mahasarakham University, Maha Sarakham, Thailand.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
  • College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
  • Pharmacy Practice Division, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.
  • UPCOR: UBU Pharmacy Clinical Outcome Research Group, Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.

ORCID-Profile: Jirawan Vienghirun, Ratree Sawangjit, Nathorn Chaiyakunapruk, Kamlesh Khunti, Shaun Wen Huey Lee

Förderung

  • Mahasarakham University

Zitieren

APA

Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K., & Lee, S. W. H. (2026). GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70698

Vancouver

Vienghirun J, Sawangjit R, Suttiruksa S, Chaiyakunapruk N, Jinathongthai P, Khunti K, et al. GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70698

BibTeX
@article{Vienghirun2026,
  author = {Vienghirun, Jirawan and Sawangjit, Ratree and Suttiruksa, Saithip and Chaiyakunapruk, Nathorn and Jinathongthai, Peerawat and Khunti, Kamlesh and Lee, Shaun Wen Huey},
  title = {GLP ‐1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta‐Analysis of RCTs},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70698}
}
Kostenlos starten →